JOHNSON & JOHNSON — Director's Dealing 2004

Jun 4, 2004

SEC Form 3/A — Form 3/A

Issuer: BARRIER THERAPEUTICS INC (BTRX)
CIK: 0001173657
Period of Report: 2004-04-28

Reporting Person: JOHNSON & JOHNSON (10% Owner)
Reporting Person: Janssen Pharmaceutica Products, L.P. (10% Owner)
Reporting Person: Johnson & Johnson Consumer Companies, Inc. (10% Owner)
Reporting Person: JOHNSON & JOHNSON DEVELOPMENT CORP ET AL (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (2033333)		Indirect
Series A Convertible Preferred Stock	$		Common Stock (6300000)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (50000)		Indirect
Series C Convertible Preferred Stock	$		Common Stock (512820)		Indirect

Footnotes

F1: All of the outstanding shares of the Issuer's Series A Convertible Preferred Stock will convert automatically on a 2 for 1 basis into Common Stock of the Company prior to the Issuer's initial public offering.

F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by this subsidiary of the Reporting Person.

F3: All of the outstanding shares of the Issuer's Series B Convertible Preferred Stock will convert automatically on a 2 for 1 basis into Common Stock of the Company prior to the Issuer's initial public offering.

F4: All of the outstanding shares of the Issuer's Series C Convertible Preferred Stock will convert automatically on a 2 for 1 basis into Common Stock of the Company prior to the Issuer's initial public offering.

F5: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers.